Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...

Gene therapies have ridden investor mania to huge valuations but commercialization challenges have pushed market caps to the ...

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months ...

HHS Secretary Robert F. Kennedy Jr. made waves this week, firing the remaining members of the CDC’s Advisory Committee on ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into ...

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions ...

Some companies’ preferences for people who already have industry experience and the tough job market are among the hurdles ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.